Skip to content
lsd.com

Industry sponsor

Janssen Research & Development, LLC

22 registered trials on this registry, 2 recruiting now. An industry sponsor is running trials with a view to approval and sale.

22
Registered trials
2
Recruiting
11
In Phase 3
15
With results posted

Working on

Substances

Trials

All 22 trials

TrialStatusPhaseSubstanceSites
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive DisorderNCT07227454 · Janssen Research & Development, LLCRecruitingPhase 3ketamine35
A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant DepressionNCT07716098 · Janssen Research & Development, LLCRecruitingPhase 3ketamine4
A Study of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant DepressionNCT04599855 · Janssen Research & Development, LLCCompletedPhase 4ketamine54
A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant DepressionNCT02417064 · Janssen Research & Development, LLCCompletedPhase 3ketamine90
A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant DepressionNCT02418585 · Janssen Research & Development, LLCCompletedPhase 3ketamine48
A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant DepressionNCT02422186 · Janssen Research & Development, LLCCompletedPhase 3ketamine69
A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant DepressionNCT02493868 · Janssen Research & Development, LLCCompletedPhase 3ketamine155
A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant DepressionNCT02497287 · Janssen Research & Development, LLCCompletedPhase 3ketamine109
A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant DepressionNCT02782104 · Janssen Research & Development, LLCCompletedPhase 3ketamine173
54135419SUI3001: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for SuicideNCT03039192 · Janssen Research & Development, LLCCompletedPhase 3ketamine56
54135419SUI3002: A Study to Evaluate the Efficacy and Safety of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Adult Participants Assessed to be at Imminent Risk for SuicideNCT03097133 · Janssen Research & Development, LLCCompletedPhase 3ketamine61
A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant DepressionNCT03434041 · Janssen Research & Development, LLCCompletedPhase 3ketamine30
A Study of Ketamine in Patients With Treatment-resistant DepressionNCT01627782 · Janssen Research & Development, LLCCompletedPhase 2ketamine13
A Study of the Efficacy of Intravenous Esketamine in Adult Patients With Treatment-Resistant DepressionNCT01640080 · Janssen Research & Development, LLCCompletedPhase 2ketamine9
A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant DepressionNCT01998958 · Janssen Research & Development, LLCCompletedPhase 2ketamine25
A Double-blind Study to Assess the Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Participants Who Are Assessed to be at Imminent Risk for SuicideNCT02133001 · Janssen Research & Development, LLCCompletedPhase 2ketamine14
Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for SuicideNCT03185819 · Janssen Research & Development, LLCCompletedPhase 2ketamine51
A Study to Investigate Evoked Potentials as Markers of Ketamine-induced Cortical Plasticity in Patients With Major Depressive DisorderNCT01957410 · Janssen Research & Development, LLCTerminatedPhase 2ketamine1
The Effect of Minocycline on Relapse After Successful Intravenous Ketamine/Minocycline-induced Symptoms Response in Subjects With DepressionNCT01809340 · Janssen Research & Development, LLCTerminatedPhase 2ketamine12
A Study to Evaluate the Effects of a Single-Dose and Repeat-Administration of Intranasal Esketamine on On-Road Driving in Participants With Major Depressive DisorderNCT02919579 · Janssen Research & Development, LLCCompletedPhase 1ketamine1
A Study to Assess Feasibility of Using Clinician-directed and Digital Application Supported Cognitive Behavior Therapy (CBT) in Conjunction With Esketamine in Participants With Treatment-resistant DepressionNCT05268497 · Janssen Research & Development, LLCWithdrawnPhase 1ketamine5
Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD)NCT03829579 · Janssen Research & Development, LLCApproved for marketingN/Aketamine—

Sponsor attribution is the lead sponsor recorded on ClinicalTrials.gov API v2. Collaborators are not counted here. Data build 2026-08-25.